Olivier Laureau, President at Servier Foundation and Servier Group, shared a post on LinkedIn:
“Our solid 2024/25 results mark a structuring milestone for our Group. With revenue reaching €6.9 billion, up 16.2%, and EBITDA of €1.9 billion, Servier confirms the strength of its model and its ability to deliver innovation in the service of patients.
These results also reflect the success of the transformation launched ten years ago, built on sustained investment in innovation, the expansion of our international footprint, and the relevance of our differentiated strategy focused on areas of high unmet medical need.
This momentum is driven by an innovation strategy focused on three therapeutic areas, oncology, neurology and cardio-metabolism, supported by structuring investments in R&D, AI and Data.
Our governance by a foundation is a unique strength. It gives us the flexibility to pursue a long-term strategy aligned with the research, development, industrialization and market access cycles of our medicines. This singularity allows us to move forward with determination and confidence toward our 2030 ambitions.
Above all, the 2024/25 results reflect the remarkable commitment of our teams around the world, who carry our mission every day: committed to therapeutic progress to serve patient needs.”
Proceed to the video attached to the post.
More posts about Servier.